Evaluation study of galectin-3 in type-2 diabetic overweight patients with and without cardiovascular disease

The present research set out to compare Galectin-3 levels between those with type-2 diabetes, those who were overweight, and those who did not have cardiovascular disease. Assess the changes in fasting blood sugar (FBS), hemoglobin A1c (HbA1c), insulin, and lipid profiles (TC, TG, HDL, LDL and VLDL) levels between a healthy control group and those with type 2 diabetes and/or obesity with or without cardiovascular disease. Galectin-3, fasting blood sugar, hemoglobin A1c, insulin, total cholesterol, triglycerides, HDL, VLDL, and LDL levels were measured in people with type 2 diabetes and in a control group of overweight people with and without cardiovascular disease. cohort of sick people A total of 120 people participated in the study and were split into three different groups at random. In Group I, forty healthy people served as controls, while in Group II, forty people with a history of type 2 diabetes but no evidence of CVD were studied. Group IIl had 40 people who already had a history of T2DM and CVD. In both groups, participants were between the ages of 40 - 60 for the duration of the research.